Akriderm, 0.05% ointment 15 g

Pharmacodynamics

Acriderm® is a glucocorticosteroid for external use. It has anti-inflammatory, anti-allergic, anti-exudative, vasoconstrictor, antipruritic and antiproliferative effects. It inhibits leukocyte accumulation, release of lysosomal enzymes and proinflammatory mediators in the inflammation focus, inhibits phagocytosis, decreases vascular and tissue permeability and prevents inflammatory edema formation.

When applied to the skin surface, the drug performs fast and strong action in the area of inflammation, reducing the severity of objective symptoms (erythema, edema, lichenification) and subjective sensations (itching, irritation, pain).

Pharmacokinetics

Transdermal absorption of the active substance into blood is very low when the drug is applied topically in therapeutic doses. The use of occlusive dressings, inflammation and skin conditions increase transdermal absorption of betamethasone, which may increase the risk of systemic side effects.

Indications

Skin diseases amenable to glucocorticosteroid therapy:

Active ingredient

Composition

100 g of ointment contain:

the active ingredient:

betamethasone dipropionate in terms of 100% substance – 0.064 g, which is equivalent to 0.05 g of betamethasone;

excipients:

Propyl parahydroxybenzoate – 0.05 g,

Liquid paraffin (petroleum jelly) – 4 g,

Isopropyl myristate – 1 g,

Vaseline – up to 100 g.

How to take, the dosage

Interaction

There have been no clinically significant interactions with other drugs.

Special Instructions

If there is no effect of treatment within two weeks, it is recommended to consult a physician for possible clarification of the diagnosis. If irritation or hypersensitivity reactions are noted when using the drug, treatment should be stopped and a physician should be consulted. In case of secondary fungal or bacterial infection it is necessary to use appropriate medication. If there is no rapid positive effect, the use of Akriderm should be discontinued until all signs of infection are eliminated.

Long-term use of the drug on the skin of the face is not recommended. Akriderm should not be used in the eye area, as this may lead to cataracts, glaucoma, fungal infection and exacerbation of herpetic infection.

Pediatric use

Children may be more susceptible to topical GCS causing hypothalamic-pituitary-adrenal system (HPA) depression than older patients due to increased absorption of the product associated with their higher surface area to body weight ratio. The following side effects have been reported in children taking topical GCS: suppression of GYN system function, Cushing’s syndrome, linear growth retardation, delayed weight gain, increased intracranial pressure.

The symptoms of depression of adrenal cortical function in children include decreased plasma cortiazole levels and no response to ACTH stimulation. Increased intracranial pressure is manifested by a bulging fontanelle, headache, and bilateral oedema of the optic disc.

Contraindications

Side effects

Overdose

Pregnancy use

Similarities